Figure 6
Figure 6. PPAR-γ ligands decrease fMLP-induced adhesion of PMNs to fibrinogen. Human PMNs were isolated and seeded onto fibrinogen-coated plates. After 20 minutes, PMNs were treated with troglitazone (5 or 10 μM) or 15d-PGJ2 (5 or 10 μM) or vehicle for 2 hours followed by treatment with 10−7 fMLP for 45 minutes. Adherent cells were trypsinized and counted using a Coulter counter. *P < .05 compared with DMSO-treated cells. Results are expressed as the average of 3 independent experiments performed in quadruplicate. Tro indicates troglitazone; PGJ2, 15-deoxy-Δ12,14-prostaglandin J2; Ctrl, without fMLP treatment. Error bars represent SEM.

PPAR-γ ligands decrease fMLP-induced adhesion of PMNs to fibrinogen. Human PMNs were isolated and seeded onto fibrinogen-coated plates. After 20 minutes, PMNs were treated with troglitazone (5 or 10 μM) or 15d-PGJ2 (5 or 10 μM) or vehicle for 2 hours followed by treatment with 10−7 fMLP for 45 minutes. Adherent cells were trypsinized and counted using a Coulter counter. *P < .05 compared with DMSO-treated cells. Results are expressed as the average of 3 independent experiments performed in quadruplicate. Tro indicates troglitazone; PGJ2, 15-deoxy-Δ12,14-prostaglandin J2; Ctrl, without fMLP treatment. Error bars represent SEM.

Close Modal

or Create an Account

Close Modal
Close Modal